Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-RT plus PD-1 antibody for advanced solid tumors
ChiCTR2600122377Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 Monoclonal Antibody in Nonhematologic neoplasms, bronchial carcinoma, hepatocellular carcinoma (HCC) and 4 more, sponsored by Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Objective Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
Nonhematologic neoplasmsbronchial carcinomahepatocellular carcinoma (HCC)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2600122377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122377.